Arvinas(NASDAQ) ARVN

Arvinas, Inc. makes medicines to remove harmful proteins. These treatments help people with cancer and brain disorders. The company uses the body's natural system to fight disease.

Targeting Disease at the Source

• VEPPANU (vepdegestrant): FDA-approved oral treatment for adults with specific types of advanced or metastatic breast cancer.
• Oncology Pipeline: Clinical-stage drug candidates designed to treat blood cancers and solid tumors by removing mutated proteins.
• Neurology Pipeline: Investigational therapies targeting proteins linked to Parkinson's disease, progressive supranuclear palsy, and other brain conditions.
• PROTAC Platform: Technology used to identify and create new protein-degrading medicines for various health needs.

Strategic Shifts and Big Partners

• Entered global license agreement with Rigel Pharmaceuticals in the second quarter of 2026 for the commercialization of VEPPANU.
• Secured FDA approval for VEPPANU in the second quarter of 2026 for treating certain breast cancer patients.
• Completed a deal with Novartis Pharma AG in May 2024 to license a drug candidate and sell a separate asset.
• Appointed Randy Teel as President and Chief Executive Officer in the first quarter of 2026.
• Completed two workforce reductions between April 2025 and mid-2026 to streamline operations and focus on key clinical trials.

A New Way to Treat Disease

Arvinas pioneered the PROteolysis TArgeting Chimera, or PROTAC, platform. This technology tags disease-causing proteins for the body to destroy. It targets proteins that traditional drugs cannot reach.

Revenue and Results

• Revenue was $265.3 million for the six-month period ended June 30, 2026, up from $211.2 million in 2025.
• Net income was $111.8 million for the six-month period ended June 30, 2026, compared to $21.7 million in 2025.
• Research and development expenses were $113.0 million for the six-month period ended June 30, 2026, down from $159.4 million year over year.
• Cash, cash equivalents, and marketable securities totaled $567.9 million as of June 30, 2026.
• Market capitalization was $580.7 million with a price-to-earnings ratio of 0.8 as of the second quarter of 2026.

From Lab to Market

Arvinas has moved from a research firm to a commercial company with its first FDA-approved therapy. It now balances internal drug discovery with major pharmaceutical partnerships.